Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation
Details
Publication Year 2018-10,Volume 142,Issue #4,Page 1355-1358
Journal Title
Journal of Allergy and Clinical Immunology
Publication Type
Journal Article
Abstract
HAE results in swelling due to KKS dysregulation and bradykinin production. FXII initiates the KKS and we have developed a human antibody that potently inhibits FXII protease activity as a novel prophylactic therapy for HAE.
Publisher
Elsevier
Research Division(s)
Population Health And Immunity
PubMed ID
29936101
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2018-06-27 09:13:23
Last Modified: 2018-10-22 10:15:46
An error has occurred. This application may no longer respond until reloaded. Reload 🗙